Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 14,400 shares, a growth of 5.1% from the January 15th total of 13,700 shares. Currently, 2.6% of the shares of the stock are sold short. Based on an average daily volume of 401,100 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP grew its holdings in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319,280 shares of the company’s stock after purchasing an additional 249,770 shares during the quarter. Anson Funds Management LP owned about 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent SEC filing. Institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Stock Performance

Shares of BJDX stock opened at $3.41 on Wednesday. Bluejay Diagnostics has a fifty-two week low of $3.03 and a fifty-two week high of $386.72. The stock’s fifty day moving average is $3.88 and its two-hundred day moving average is $6.41. The firm has a market capitalization of $1.88 million, a P/E ratio of 0.00 and a beta of 0.46.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.